Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial

Journal of Clinical Oncology

Volumn 18, Issue 3, 2000, Pages 623-631

  Bonomi, Philip ^a   Kim, KyungMann ^a   Fairclough, Diane ^a   Cella, David ^a   Kugler, John ^a   Rowinsky, Eric ^a   Jiroutek, Michael ^a   Johnson, David ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0033950286     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.3.623     Document Type: Article

References (30)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics. CA Cancer J Clin 49:8-31, 1999
2. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough. J Clin Oncol 11:1866-1872, 1993
3. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995
4. Ruckdeschel JC, Finkelstein DM, Mason BA, et al: Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST:2575, generation V - A randomized comparison of four cisplatin-containing regimens. J Clin Oncol 3:72-79, 1985
5. Ruckdeschel JC, Finkelstein DN, Ettinger D, et al: A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4:14-22, 1986
6. Bonomi P, Finkelstein DN, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989
7. Chang AT, Kim K, Glick J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-392, 1993
8. Murphy WL, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384-387, 1993
9. Finkelstein DM, Ettinger DS, Ruckdeschel JC: Long-term survivors in metastatic non-small cell lung cancer: An Eastern Cooperative Group study. J Clin Oncol 4:702-709, 1986
10. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 15:649-655, 1982
11. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
12. Lan KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
13. Fisher RA: Statistical methods for research workers. Oliver and Boyd, Edinburgh, United Kingdom, 1925
14. Kruskal WH, Wallis WA: Use of ranks in one criterion variance analysis. J Am Stat Assoc 47:583-612, 1952
15. Kaplan FL, Meier P: Non-parametric estimation from incomplete estimation. J Am Stat Assoc 53:457-481, 1958
16. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
17. Longnecker SM, Donehower RC, Cates WE, et al: High performance liquid chromatographic assay for Taxol (NSC 125973) in human plasma and urine pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53-59, 1981
18. Rowinsky EK, Chaundry V, Forestierre A, et al: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010-2020, 1993
19. Cella DG, Bonomi AE, Lloyd SR, et al: Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220, 1995
20. Fairclough DL, Peterson H, Cella D, et al: Comparison of mode based methods dependent on missing data mechanism in two clinical trials of cancer therapy. Stat Med 17:781-796, 1998
21. Aisner J, Hansen HH: Commentary: Current status, of chemotherapy for non-small cell lung cancer. Cancer Treat Rep 65:979-986, 1981
22. Giaccone G, Splinter TAW, Debruyne C, et al: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 16:2133-2141, 1998
23. Shepherd F, Ramlau R, Mattson K, et al: Randomized study of taxotere (tax) versus best supportive care (BSC) in non-small-cell lung cancer (MSCLC) patients previously treated with Platinum-containing chemotheraphy. Proc. Am Soc Clin Oncol 18:463a, 1999 (abstr 1784)
24. Gatzemeier U, Von Pawel J, Gottfield M, et al: Phase III comparative study of high-dose cisplatin versus a combination regimen of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 17:454a, 1998 (abstr 1748)
25. Belani CP, Natale RB, Lee JS, et al: Randomized phase III trial comparing cisplatin-etoposide versus carboplatin-paclitaxel in advanced and metastatic non-small-cell lung cancer. Proc Am Soc Clin Oncol 17:455a, 1998 (abstr 1751)
26. Raymond E, Hanauske A, Faivre S, et al: Effects of prolonged versus short-term exposure paclitaxel on human tumor colony forming units. Anticancer Drugs 8:379-385, 1997
27. Kelly K, Pan Z, Murphy J, et al: A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res 3:1117-1123, 1997
28. Huizing MT, Giaccone G, Van Warmerdam LJ, et al: Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and dose-sequencing studies in patients with non-small-cell lung cancer. J Clin Oncol 15:317-329, 1997
29. Kelly K, Crowley J, Bunn PA, et al: A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group trial. Proc Am Soc Clin Oncol 18:461a, 1999 (abstr 1777)
30. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin-vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Cln Oncol 16:2459-2465, 1998